- Home
- BEAM vs BWLP Comparison
BEAM vs BWLP Comparison
Compare BEAM & BWLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- BWLP
- Stock Information
- Founded
- BEAM 2017
- BWLP 1935
- Country
- BEAM United States
- BWLP Singapore
- Employees
- BEAM N/A
- BWLP N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- BWLP Marine Transportation
- Sector
- BEAM Health Care
- BWLP Consumer Discretionary
- Exchange
- BEAM Nasdaq
- BWLP Nasdaq
- Market Cap
- BEAM 1.6B
- BWLP 1.6B
- IPO Year
- BEAM 2020
- BWLP N/A
- Fundamental
- Price
- BEAM $20.01
- BWLP $12.50
- Analyst Decision
- BEAM Strong Buy
- BWLP
- Analyst Count
- BEAM 11
- BWLP 0
- Target Price
- BEAM $48.90
- BWLP N/A
- AVG Volume (30 Days)
- BEAM 2.0M
- BWLP 428.2K
- Earning Date
- BEAM 08-05-2025
- BWLP 08-27-2025
- Dividend Yield
- BEAM N/A
- BWLP 13.60%
- EPS Growth
- BEAM N/A
- BWLP N/A
- EPS
- BEAM N/A
- BWLP 1.86
- Revenue
- BEAM $63,578,000.00
- BWLP $3,387,328,000.00
- Revenue This Year
- BEAM N/A
- BWLP N/A
- Revenue Next Year
- BEAM $8.82
- BWLP $2.04
- P/E Ratio
- BEAM N/A
- BWLP $7.23
- Revenue Growth
- BEAM N/A
- BWLP 9.53
- 52 Week Low
- BEAM $13.53
- BWLP $7.86
- 52 Week High
- BEAM $35.25
- BWLP $19.36
- Technical
- Relative Strength Index (RSI)
- BEAM 68.31
- BWLP 65.89
- Support Level
- BEAM $16.59
- BWLP $11.58
- Resistance Level
- BEAM $17.38
- BWLP $12.18
- Average True Range (ATR)
- BEAM 1.10
- BWLP 0.30
- MACD
- BEAM 0.35
- BWLP 0.01
- Stochastic Oscillator
- BEAM 89.70
- BWLP 97.87
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.